Introduction
The previous article introduced the real options framework and explained why DCF analysis undervalues investments with embedded flexibility. This article examines how real options are applied in the three sectors where they matter most: natural resources (where the option to develop or defer is driven by commodity price volatility), pharmaceuticals (where sequential clinical phase gates create compound options), and technology (where platform investments carry expansion options into adjacent markets).
Natural Resources: The Option to Develop or Defer
The Core Option
A mining company holding undeveloped mineral rights owns a real option: the right to develop the deposit at the cost of building the mine. The company will exercise this option (invest in development) only if the commodity price is high enough to make the mine profitable. If prices are low, the company defers development and waits.
This option has significant value because:
- The downside is limited: If commodity prices stay low, the company simply does not invest. The cost of holding undeveloped rights is minimal (property taxes, minimal maintenance).
- The upside is substantial: If commodity prices rise, the mine becomes highly profitable, and the development option is deeply "in the money."
- Higher price volatility increases option value: Gold, copper, and lithium prices are volatile. The wider the range of possible future prices, the more valuable the option to develop only when prices are favorable.
Application in Oil and Gas
Oil and gas companies face similar decisions about developing or deferring wells, fields, and acreage. The PV-10 (at the current price) may show a development project as marginally economic, but the option value of waiting for higher oil prices (or better drilling technology) may make deferral the optimal strategy. Real options analysis quantifies this "wait value" that the standard NAV misses.
Pharmaceuticals: Compound Options at Each Phase Gate
Sequential Decision Points
Drug development is a multi-stage process where management makes a go/no-go decision at each phase gate: Preclinical to Phase I, Phase I to Phase II, Phase II to Phase III, Phase III to FDA submission. Each decision point is an option: the company pays the cost of the next clinical phase (the "exercise price") only if the results from the current phase are sufficiently promising.
This creates a compound option structure: the Phase I option gives the company the right to purchase the Phase II option (by paying Phase II trial costs), which gives the right to purchase the Phase III option, and so on. The value of the entire pipeline is the value of this chain of nested options.
How Real Options Differs from rNPV
The risk-adjusted NPV (rNPV) methodology captures the binary risk of clinical trials through probability weighting. Real options goes further by explicitly valuing the flexibility to stop investing at each stage. In rNPV, the probabilities are fixed; in real options, management's decision to continue or abandon is modeled as an optimal exercise strategy based on the information available at each gate.
The practical difference is that real options typically produces a higher value than rNPV for early-stage assets, because it captures the value of the flexibility that rNPV treats as implicit. For late-stage assets (Phase III and beyond), the difference is smaller because the remaining optionality is limited.
Technology: Platform Expansion Options
The Option to Expand
Technology platforms create options that are difficult to value through standard DCF because the future applications of the platform are not yet defined. When Amazon built AWS, the initial business plan was cloud infrastructure for developers. The expansion into AI services, machine learning, database management, and IoT connectivity represented options that were embedded in the platform but not projected in the original business plan.
A standard DCF at the time of AWS's launch would have valued the known cloud infrastructure business. The real options framework recognizes that the platform architecture itself creates options to expand into adjacent markets at relatively low incremental cost, and these options have value proportional to the uncertainty about which markets will emerge.
Why Technology Companies Trade at "Premium" Multiples
Part of the explanation for technology companies trading at EV/Revenue multiples that appear expensive on a DCF basis is that the market is pricing embedded real options:
- A SaaS platform with a large installed base has the option to cross-sell new products to existing customers at low incremental acquisition cost
- An AI company with a proprietary data set has options to enter markets that do not yet exist
- A marketplace with network effects has the option to expand geographically or into adjacent categories
These options do not appear in the DCF because they represent future decisions that have not yet been made. But the market prices them implicitly through premium multiples.
- Compound Option
An option whose value depends on another option. In pharmaceutical valuation, the Phase I trial is a compound option: exercising it (completing Phase I successfully) gives the company the option to exercise Phase II (investing in the next clinical stage). The value of the Phase I option includes not just the direct payoff from Phase I results but also the value of the subsequent options it creates. Compound options are the most relevant real option structure for multi-stage investments.
Practical Limitations
Despite the theoretical appeal, real options analysis has significant practical limitations that explain why it remains supplementary rather than primary in most investment banking work:
- Input estimation: The Black-Scholes and binomial models require volatility as a key input. For financial options, volatility is observable from market data. For real options, volatility must be estimated from proxy data (commodity price volatility, comparable company stock volatility), which introduces significant subjectivity.
- Model complexity: Multi-stage compound options with correlated variables require sophisticated modeling that is time-consuming and difficult to explain to non-technical audiences.
- Over-optimism risk: Because real options analysis tends to produce higher values than DCF (by capturing upside flexibility), it can be used to justify overpaying for speculative investments. The flexibility has value only if management actually exercises the options optimally, which is not guaranteed.
- Liquidity and exclusivity: Financial options are exercisable on liquid, tradable assets. Real options often involve illiquid, non-tradable assets (a mine, a clinical trial, a platform), and the owner may not have exclusive rights (competitors may develop substitute assets).
- Compound Option (Sequential Real Option)
A real option where exercising the first option grants the holder the right to exercise a subsequent option, creating a chain of embedded decisions. Pharmaceutical drug development is the classic compound option: investing in Phase I (the first option) gives the company the right to invest in Phase II (the second option), which gives the right to invest in Phase III, and so on. Each "exercise" requires additional capital investment, and the decision is based on the information gained from the prior stage. Compound options are more valuable than simple options because the total investment is spread across multiple decision points, allowing the company to abandon at any stage if the results are unfavorable. The alternative (committing the full development budget upfront with no option to stop) would be worth significantly less because it eliminates the flexibility that the staged approach provides.
Free Interview PDF Guide